Emerald Health Therapeutics, Inc. (TSXV:EMH) signed a definitive agreement to acquire remaining 35% stake in Northern Vine Canada Inc. from Abattis Bioceuticals Corp. (OTCPK:ATTB.F) for CAD 10 million on July 19, 2018. Under the terms of the agreement, Emerald Health will pay CAD 2 million in cash and CAD 4 million in shares of its common stock. The agreement also includes a milestone payment of CAD 4 million in common shares if Northern Vine and/or Emerald receive gross revenue of CAD 10 million from the sale of products or services introduced by Abattis. Northern Vine will operate independently of Emerald, post-completion.

Emerald Health Therapeutics, Inc. (TSXV:EMH) completed the acquisition of 35% stake in Northern Vine Canada Inc. from Abattis Bioceuticals Corp. (OTCPK:ATTB.F) on August 14, 2018.